Does the media refer more to REGN or UTHR?

In the previous week, Regeneron Pharmaceuticals had 32 more articles in the media than United Therapeutics. MarketBeat recorded 54 mentions for Regeneron Pharmaceuticals and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Regeneron Pharmaceuticals' score of 0.60 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 21 Very Positive mention(s) 3 Positive mention(s) 26 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 18 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ALNY or UTHR?

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than United Therapeutics. MarketBeat recorded 23 mentions for Alnylam Pharmaceuticals and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Alnylam Pharmaceuticals' score of 0.72 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 10 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 18 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor UTHR or BIIB?

In the previous week, United Therapeutics had 1 more articles in the media than Biogen. MarketBeat recorded 22 mentions for United Therapeutics and 21 mentions for Biogen. United Therapeutics' average media sentiment score of 1.59 beat Biogen's score of 0.60 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 18 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biogen 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer UTHR or INCY?

In the previous week, Incyte had 6 more articles in the media than United Therapeutics. MarketBeat recorded 28 mentions for Incyte and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Incyte's score of 1.15 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 18 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Incyte 19 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NBIX or UTHR?

In the previous week, Neurocrine Biosciences had 5 more articles in the media than United Therapeutics. MarketBeat recorded 27 mentions for Neurocrine Biosciences and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Neurocrine Biosciences' score of 1.07 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 14 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 18 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

United Therapeutics (UTHR) Competitors

$528.47 -1.06 (-0.20%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$528.61 +0.14 (+0.03%)

As of 07/24/2026 07:34 PM Eastern

Compare

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

Should you buy United Therapeutics stock or one of its competitors? MarketBeat compares United Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with United Therapeutics include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Regeneron Pharmaceuticals presently has a consensus target price of $787.88, indicating a potential upside of 20.10%. United Therapeutics has a consensus target price of $648.33, indicating a potential upside of 22.68%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe United Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Regeneron Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 32 more articles in the media than United Therapeutics. MarketBeat recorded 54 mentions for Regeneron Pharmaceuticals and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Regeneron Pharmaceuticals' score of 0.60 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	21 Very Positive mention(s)	3 Positive mention(s)	26 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	18 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.84	$4.50B	$41.04	15.98
United Therapeutics	$3.18B	7.05	$1.33B	$27.09	19.51

United Therapeutics has a net margin of 40.62% compared to Regeneron Pharmaceuticals' net margin of 29.65%. United Therapeutics' return on equity of 19.24% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
United Therapeutics	40.62%	19.24%	17.25%

Summary

United Therapeutics beats Regeneron Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Alnylam Pharmaceuticals presently has a consensus price target of $452.13, indicating a potential upside of 66.37%. United Therapeutics has a consensus price target of $648.33, indicating a potential upside of 22.68%. Given Alnylam Pharmaceuticals' higher possible upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Alnylam Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

United Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	9.77	$313.75M	$3.66	74.25
United Therapeutics	$3.18B	7.05	$1.33B	$27.09	19.51

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than United Therapeutics. MarketBeat recorded 23 mentions for Alnylam Pharmaceuticals and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Alnylam Pharmaceuticals' score of 0.72 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	10 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	18 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

United Therapeutics has a net margin of 40.62% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
United Therapeutics	40.62%	19.24%	17.25%

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Alnylam Pharmaceuticals and United Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Biogen?

United Therapeutics (NASDAQ:UTHR) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

United Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Biogen has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

United Therapeutics has higher earnings, but lower revenue than Biogen. United Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.05	$1.33B	$27.09	19.51
Biogen	$9.89B	3.02	$1.29B	$9.32	21.69

United Therapeutics has a net margin of 40.62% compared to Biogen's net margin of 13.81%. United Therapeutics' return on equity of 19.24% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Biogen	13.81%	12.83%	8.01%

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

United Therapeutics currently has a consensus price target of $648.33, indicating a potential upside of 22.68%. Biogen has a consensus price target of $220.57, indicating a potential upside of 9.09%. Given United Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe United Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Biogen	2 Sell rating(s)	12 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.53

In the previous week, United Therapeutics had 1 more articles in the media than Biogen. MarketBeat recorded 22 mentions for United Therapeutics and 21 mentions for Biogen. United Therapeutics' average media sentiment score of 1.59 beat Biogen's score of 0.60 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	18 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biogen	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Biogen on 13 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Incyte?

United Therapeutics (NASDAQ:UTHR) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Incyte had 6 more articles in the media than United Therapeutics. MarketBeat recorded 28 mentions for Incyte and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Incyte's score of 1.15 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	18 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Incyte	19 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics presently has a consensus target price of $648.33, suggesting a potential upside of 22.68%. Incyte has a consensus target price of $111.10, suggesting a potential downside of 5.58%. Given United Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe United Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36

United Therapeutics has a net margin of 40.62% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Incyte	26.71%	26.66%	19.77%

United Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

United Therapeutics has higher earnings, but lower revenue than Incyte. Incyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.05	$1.33B	$27.09	19.51
Incyte	$5.36B	4.39	$1.29B	$7.08	16.62

Summary

United Therapeutics beats Incyte on 9 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

United Therapeutics has a net margin of 40.62% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
United Therapeutics	40.62%	19.24%	17.25%

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neurocrine Biosciences currently has a consensus target price of $194.05, suggesting a potential upside of 10.40%. United Therapeutics has a consensus target price of $648.33, suggesting a potential upside of 22.68%. Given United Therapeutics' higher probable upside, analysts clearly believe United Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	6.18	$478.60M	$6.49	27.08
United Therapeutics	$3.18B	7.05	$1.33B	$27.09	19.51

In the previous week, Neurocrine Biosciences had 5 more articles in the media than United Therapeutics. MarketBeat recorded 27 mentions for Neurocrine Biosciences and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Neurocrine Biosciences' score of 1.07 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	14 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	18 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Neurocrine Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Summary

United Therapeutics beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTHR vs. The Competition

Export

Metric	United Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.48B	$3.08B	$6.89B	$12.27B
Dividend Yield	N/A	2.07%	2.67%	9.80%
P/E Ratio	19.51	20.29	26.98	23.71
Price / Sales	7.05	353.05	517.83	87.12
Price / Cash	16.05	27.62	50.54	59.64
Price / Book	3.21	4.13	10.28	6.07
Net Income	$1.33B	$65.94M	$3.60B	$331.84M
7 Day Performance	-1.34%	-4.18%	-1.25%	-1.53%
1 Month Performance	-2.75%	-3.76%	-0.35%	-2.46%
1 Year Performance	73.55%	9.93%	18.40%	13.66%

United Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTHR United Therapeutics	4.6863 of 5 stars	$528.47 -0.2%	$648.33 +22.7%	+72.5%	$22.48B	$3.18B	19.51	1,400	Positive News Analyst Forecast
REGN Regeneron Pharmaceuticals	4.4574 of 5 stars	$672.15 -0.7%	$787.67 +17.2%	+16.2%	$71.54B	$14.34B	16.38	15,410	Trending News Upcoming Earnings Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.6043 of 5 stars	$272.67 +1.9%	$455.31 +67.0%	-17.1%	$35.71B	$3.71B	74.50	2,770	News Coverage Upcoming Earnings Analyst Forecast
BIIB Biogen	3.9245 of 5 stars	$199.95 -2.9%	$220.04 +10.0%	+52.5%	$30.41B	$9.89B	21.45	7,500	Upcoming Earnings Analyst Forecast
INCY Incyte	3.1919 of 5 stars	$115.65 -1.4%	$109.95 -4.9%	+66.9%	$23.42B	$5.14B	16.33	2,844	Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTHR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Summary

How does United Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does United Therapeutics compare to Biogen?

Summary

How does United Therapeutics compare to Incyte?

Summary

How does United Therapeutics compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Do analysts prefer REGN or UTHR?

Which has more risk & volatility, REGN or UTHR?

Does the media refer more to REGN or UTHR?

Do insiders and institutionals believe in REGN or UTHR?

Which has stronger earnings & valuation, REGN or UTHR?

Is REGN or UTHR more profitable?

Summary

How does United Therapeutics compare to Alnylam Pharmaceuticals?

Do analysts recommend ALNY or UTHR?

Which has more volatility & risk, ALNY or UTHR?

Which has better earnings & valuation, ALNY or UTHR?

Does the media refer more to ALNY or UTHR?

Is ALNY or UTHR more profitable?

Do institutionals and insiders believe in ALNY or UTHR?

Summary

How does United Therapeutics compare to Biogen?

Which has more risk & volatility, UTHR or BIIB?

Which has higher valuation & earnings, UTHR or BIIB?

Is UTHR or BIIB more profitable?

Do institutionals and insiders hold more shares of UTHR or BIIB?

Do analysts recommend UTHR or BIIB?

Does the media favor UTHR or BIIB?

Summary

How does United Therapeutics compare to Incyte?

Do institutionals and insiders hold more shares of UTHR or INCY?

Does the media prefer UTHR or INCY?

Do analysts recommend UTHR or INCY?

Is UTHR or INCY more profitable?

Which has more volatility and risk, UTHR or INCY?

Which has higher valuation and earnings, UTHR or INCY?

Summary

How does United Therapeutics compare to Neurocrine Biosciences?

Is NBIX or UTHR more profitable?

Do insiders & institutionals have more ownership in NBIX or UTHR?

Do analysts prefer NBIX or UTHR?

Which has preferable earnings & valuation, NBIX or UTHR?

Does the media refer more to NBIX or UTHR?

Which has more risk and volatility, NBIX or UTHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools